Intrahepatic Cholangiocarcinoma: Understanding Your Pathology Report

by Stephanie Reid, MD FRCPC
November 18, 2026


Print this article

Intrahepatic cholangiocarcinoma is a cancer that starts in the small bile ducts inside the liver. Bile ducts are thin tubes that carry bile, a digestive fluid made by liver cells, toward the intestine. Intrahepatic cholangiocarcinoma is the second most common cancer that starts in the liver, after hepatocellular carcinoma. It accounts for about 10% to 15% of these cancers. Because it grows inside the liver and rarely blocks bile flow early, it often causes no symptoms until it is large.

This article explains what intrahepatic cholangiocarcinoma is and how its small-duct and large-duct types differ. It also walks through what your pathology report says about the tumor’s grade, size, margins, lymph nodes, genetic changes, and stage. Cancers that start in the bile ducts outside the liver are described in our article on extrahepatic cholangiocarcinoma.

What causes intrahepatic cholangiocarcinoma?

Intrahepatic cholangiocarcinoma usually develops after years of injury to the liver or its bile ducts. Ongoing injury allows genetic changes to build up in the cells lining the ducts. Many people have no known risk factors. Conditions linked to a higher risk include:

  • Chronic liver disease. Cirrhosis, long-term hepatitis B or C infection, and fatty liver disease linked to obesity and diabetes all raise the risk.
  • Primary sclerosing cholangitis. This scarring disease of the bile ducts is a strong risk factor, especially for the large duct type. Our article on primary sclerosing cholangitis explains how the risk is monitored.
  • Stones inside the liver’s ducts. Long-standing stones in the bile ducts within the liver cause repeated inflammation.
  • Liver flukes. These parasites are an important cause in parts of Southeast Asia.

What are the symptoms of intrahepatic cholangiocarcinoma?

Early intrahepatic cholangiocarcinoma often causes no symptoms. Many tumors are found incidentally on scans done for another reason. As the tumor grows, people may notice pain in the upper right abdomen, weight loss, tiredness, or a poor appetite. Yellowing of the skin and eyes, called jaundice, is less common than with cancers outside the liver. It usually means the tumor has reached a larger bile duct near the center of the liver.

How is the diagnosis made?

The diagnosis of intrahepatic cholangiocarcinoma usually starts with a CT scan or MRI that shows a mass in the liver. Imaging can suggest the diagnosis, but a tissue sample is almost always needed to confirm it. Doctors usually collect the sample by passing a needle through the skin into the mass, called a core needle biopsy or fine needle aspiration. Sometimes the diagnosis is made only after the tumor is removed by surgery.

Under the microscope, a pathologist sees an adenocarcinoma. This means the cancer cells form glands or tube-like structures within dense, scar-like tissue called desmoplasia. Pathologists often use immunohistochemistry, such as a stain for cytokeratin 7, to confirm that the tumor is made of bile duct-type cells.

No single test proves that a liver adenocarcinoma started there. Cancers from the pancreas, stomach, colon, and other organs can spread to the liver and look very similar. For this reason, your doctors combine the biopsy with imaging of the rest of the body before making the final diagnosis. Imaging also shows whether the cancer has spread to lymph nodes or other organs.

What are the different types of intrahepatic cholangiocarcinoma?

The World Health Organization (WHO) classification of digestive system tumors, 5th edition (2019), divides intrahepatic cholangiocarcinoma into two types. The College of American Pathologists (CAP) reporting checklist uses the same types, so your report may name one of them. The two types start in different parts of the bile duct tree, have different genetic changes, and behave differently.

  • Small duct type. This type starts in the tiny bile ducts near the edge of the liver and forms a single, well-defined mass. It usually does not make mucus and is often linked to chronic hepatitis, cirrhosis, or fatty liver disease. Changes in the IDH1, IDH2, FGFR2, and BAP1 genes are found mainly in this type. It generally has a better outlook than the large duct type.
  • Large duct type. This type starts in the larger bile ducts near the center of the liver. It tends to grow along the ducts and often makes mucin, a type of mucus. It looks and behaves like cancers of the bile ducts outside the liver. It is linked to primary sclerosing cholangitis, bile duct stones, and liver flukes. KRAS mutations are found mainly in this type.

A variant of the small duct type called cholangiolocarcinoma is made of small, bland cells forming cord-like structures. It has a better outlook than the usual small duct type. Some tumors contain both hepatocellular carcinoma and cholangiocarcinoma. These are reported as combined hepatocellular-cholangiocarcinoma, which is a separate diagnosis.

Histologic grade

The grade of intrahepatic cholangiocarcinoma describes how closely the cancer cells resemble normal bile duct cells. Pathologists judge it mainly by how well the cells form glands. The grade helps predict how the tumor will behave and is one factor your care team considers when planning treatment.

  • Well differentiated (G1). Most of the tumor forms well-shaped glands that look close to normal ducts. These tumors tend to grow more slowly.
  • Moderately differentiated (G2). The tumor forms glands, but they are more irregular. This is the most common grade.
  • Poorly differentiated (G3). Few glands are formed, and the cells look very abnormal. These tumors are more likely to spread.

Tumor size and number of tumors

For intrahepatic cholangiocarcinoma, the pathologist measures the largest tumor and counts how many separate tumors are in the liver. Both findings help determine tumor stage, because a single tumor 5 cm or smaller is lower stage than a single tumor larger than 5 cm. When there is more than one tumor, the smaller ones may be called satellite nodules. Multiple tumors place the cancer in a higher stage, whatever their size, and are linked to a higher risk of the cancer coming back.

Perineural invasion

In intrahepatic cholangiocarcinoma, perineural invasion means cancer cells are growing around or along a nerve. It is more common in the large duct type. Nerves can act as a pathway, letting cancer cells travel beyond the visible edge of the tumor. Perineural invasion is linked to a higher chance of the cancer coming back after surgery.

Lymphovascular invasion

Lymphovascular invasion means cancer cells are seen inside a blood vessel or lymphatic channel. In intrahepatic cholangiocarcinoma, cancer cells in a blood vessel are called vascular invasion, and this finding changes the stage. A single tumor with vascular invasion is staged as pT2, even if it is small.

  • Microvascular invasion. Cancer cells are found in small vessels that can only be seen under the microscope. It is linked to a higher risk of the cancer returning in the liver.
  • Major vascular invasion. The tumor grows into a large vein, such as a branch of the portal vein or a hepatic vein. This is usually seen on imaging or during surgery. It can affect whether the tumor can be safely removed.

Surgical margins

A margin is the edge of liver tissue that the surgeon cuts to remove the intrahepatic cholangiocarcinoma. The pathologist checks the cut surface of the liver, called the hepatic parenchymal margin. If the surgeon cuts a bile duct, the pathologist checks its margin as well.

  • Negative. No cancer cells are seen at any cut edge. Many reports also give the distance from the cancer to the closest margin, measured in centimeters or millimeters.
  • Positive. Cancer cells reach a cut edge. This raises the chance that some cancer was left behind, and your team will take it into account when planning further treatment.

Our article on surgical margins in your pathology report explains how margins are examined in different organs.

Lymph nodes

Lymph nodes are small immune organs that drain fluid from nearby tissues. Intrahepatic cholangiocarcinoma can spread to the lymph nodes near the liver, the bile ducts, and the pancreas. Surgeons often remove these nodes and examine them under the microscope. The American Joint Committee on Cancer (AJCC) 8th edition recommends examining at least 6 nodes for accurate staging.

  • Negative. None of the nodes examined contain cancer.
  • Positive. Cancer is found in one or more nodes, which is among the most important predictors of the cancer returning after surgery.

The report lists the number of nodes examined and how many contain cancer. Our article on lymph nodes in your pathology report explains how to read these numbers.

Biomarker and molecular testing

Biomarker testing is especially important in intrahepatic cholangiocarcinoma, because it has more treatable genetic changes than most other cancers of the digestive system. Testing is recommended for anyone with advanced disease. It is usually done with next-generation sequencing, which checks many genes at once in a tumor sample. A few results, such as HER2, also use tissue stains.

IDH1 and IDH2

IDH1 and IDH2 are genes that make enzymes used in normal cell metabolism. A mutation in either gene causes the cell to make a substance that blocks normal cell maturation. In a large study of advanced intrahepatic cholangiocarcinoma, about 14% had an IDH1 change and about 4% had an IDH2 change.

  • IDH1 and IDH2 wild type. No mutation was found in either gene. This is the most common result.
  • IDH1 mutation. Ivosidenib, a drug that blocks the abnormal IDH1 enzyme, was approved by the FDA in 2021 and by Health Canada in 2024. Both approvals are for cancers that have grown after earlier treatment.
  • IDH2 mutation. No targeted drug is currently approved for cholangiocarcinoma with this result. Clinical trials may be available.

FGFR2 fusions

FGFR2 is a gene that makes a growth signal receptor. In about 1 in 10 intrahepatic cholangiocarcinomas, the gene joins with another gene, creating a fusion that keeps the growth signal switched on. These fusions are found almost exclusively in the small-duct type.

  • No FGFR2 fusion. No fusion was found, which is the most common result.
  • FGFR2 fusion or rearrangement. Pemigatinib received accelerated approval from the FDA in 2020 for previously treated cholangiocarcinoma with this result, and Health Canada authorized it with conditions. Futibatinib received accelerated approval from the FDA in 2022 for previously treated intrahepatic cholangiocarcinoma with this result.

HER2

HER2 is a protein on the cell surface that sends growth signals. HER2 overexpression is uncommon in intrahepatic cholangiocarcinoma and is seen mostly in the large-duct type. It is tested with immunohistochemistry, scored from 0 to 3+, and sometimes with in situ hybridization.

  • Negative (0 or 1+). The tumor cells make little or no HER2.
  • Equivocal (2+). The result is uncertain, and in situ hybridization is usually done to look for extra copies of the gene.
  • Positive (3+). The tumor cells make a large amount of HER2. Zanidatamab received accelerated approval from the FDA in 2024 for previously treated biliary tract cancer with this result, and Health Canada authorized it with conditions in 2026.

KRAS

KRAS is a gene that passes growth signals inside the cell. KRAS mutations are found mainly in the large duct type and are linked to a worse outlook.

  • No KRAS mutation (wild type). The KRAS gene is normal.
  • KRAS mutation. No drug is currently approved for cholangiocarcinoma based on this result. The specific mutation, such as G12C, may make you eligible for a clinical trial.

BRAF V600E

  • No BRAF V600E mutation. This specific change in the BRAF gene is not present. This is the usual result.
  • BRAF V600E mutation. This uncommon change can be targeted. Dabrafenib with trametinib received accelerated approval from the FDA in 2022 for solid tumors with this change that have grown after earlier treatment.

NTRK fusions

  • No NTRK fusion. None of the NTRK genes is joined to another gene. This is the usual result.
  • NTRK fusion. This rare change can be targeted. Larotrectinib and entrectinib are authorized with conditions by Health Canada for solid tumors with this result. Our article on NTRK fusions in cancer explains these approvals.

Mismatch repair (MMR) and microsatellite instability (MSI)

  • Proficient (pMMR) or microsatellite stable (MSS). All four mismatch repair proteins are present, or the DNA shows no instability. This is the result in most intrahepatic cholangiocarcinomas.
  • Deficient (dMMR) or MSI-high. One or more proteins are missing. Pembrolizumab is approved by the FDA (2017) and Health Canada for unresectable or metastatic solid tumors with this result that have grown after earlier treatment. A deficient result can also point to Lynch syndrome, an inherited condition, and genetic counseling may be offered.

Other genetic changes

Sequencing often reports changes in other genes, such as BAP1, TP53, and ARID1A. No targeted drug is approved for cholangiocarcinoma based on these results. These tests can help confirm the small-duct or large-duct type, and they may make you eligible for a clinical trial.

The Biomarkers and Genetic Testing section explains these tests in more detail, including our article on MMR and MSI in gastrointestinal cancers.

Pathologic stage (pTNM)

The pathologic stage of intrahepatic cholangiocarcinoma is based on the AJCC 8th edition. It combines the tumor findings (pT) and the lymph node findings (pN). Spread to distant organs (M) is usually found on imaging rather than in the surgical specimen. Our article on TNM staging explains the system.

Tumor stage (pT)

  • pTis. Carcinoma in situ. Abnormal cells are confined to the bile duct lining and have not invaded.
  • pT1a. A single tumor 5 cm or smaller with no vascular invasion.
  • pT1b. A single tumor larger than 5 cm with no vascular invasion.
  • pT2. A single tumor of any size with vascular invasion, or more than one tumor.
  • pT3. The tumor has grown through the thin lining on the outer surface of the liver, called the visceral peritoneum.
  • pT4. The tumor has grown directly into nearby structures outside the liver, such as the stomach, intestine, or diaphragm.

Nodal stage (pN)

  • pN0. No cancer is found in the regional lymph nodes examined.
  • pN1. Cancer is found in one or more regional lymph nodes.

What is the prognosis?

The prognosis for intrahepatic cholangiocarcinoma depends most on whether the tumor can be completely removed. In a large international study of people who had surgery, about 40% were alive five years later. For people whose cancer cannot be removed, only about 5% to 10% are alive at five years. In the trial that led to the approval of durvalumab with chemotherapy, the median survival for advanced cancer was about 13 months.

Findings in the pathology report that are linked to a higher risk of the cancer coming back include:

  • Lymph node spread. Cancer in one or more lymph nodes.
  • Vascular invasion. Cancer cells inside blood vessels, especially large veins.
  • Multiple tumors. More than one tumor, including satellite nodules.
  • Positive margin. Cancer cells at the cut edge of the liver.
  • Other features. Perineural invasion, a poorly differentiated grade, a tumor larger than 5 cm, and the large duct type.

A tumor with an IDH1 mutation or an FGFR2 fusion can be treated with a targeted drug if it grows after first treatment. Many people live longer than the average figures suggest, and your care team can explain what your own findings mean.

What happens after the diagnosis?

Once intrahepatic cholangiocarcinoma is confirmed, a team that usually includes a liver surgeon, medical oncologist, radiation oncologist, and interventional radiologist reviews the scans and pathology. The first question is whether the tumor can be safely removed.

  • Surgery. A partial hepatectomy removes the part of the liver containing the tumor. Surgeons often remove nearby lymph nodes at the same time for staging.
  • Treatment after surgery. The American Society of Clinical Oncology (ASCO) guideline, first published in 2019, recommends offering six months of capecitabine chemotherapy after surgery for biliary tract cancer.
  • Treatment directed at the liver. When surgery is not possible, some centers use treatments that deliver chemotherapy or radiation directly to the tumor through its blood supply, or focused radiation from outside the body.
  • Liver transplant. Transplant for intrahepatic cholangiocarcinoma is offered only in selected cases, mostly within clinical studies at specialized centers.

For advanced cancer, the first treatment is usually gemcitabine and cisplatin chemotherapy combined with immunotherapy:

  • Durvalumab. Approved with gemcitabine and cisplatin by the FDA in September 2022, and authorized by Health Canada.
  • Pembrolizumab. Approved with gemcitabine and cisplatin by the FDA in October 2023, and approved by Health Canada.

If the cancer grows after first treatment, the biomarker results guide whether a targeted drug may be considered. Treating the underlying liver disease, such as hepatitis B or C, remains important throughout. Follow-up usually includes regular scans and blood tests, which may include the tumor marker CA 19-9.

Questions to ask your doctor

  • Is my tumor small-duct or large-duct?
  • What grade is my cancer?
  • How large was the tumor, and was there more than one tumor in my liver?
  • Was vascular invasion found, and was it microscopic or in a large vein?
  • Was perineural invasion found?
  • Were the margins negative, and how close was the cancer to the cut edge?
  • How many lymph nodes were removed, and did any contain cancer?
  • What is the pathologic stage of my cancer?
  • Was my tumor tested for IDH1, FGFR2, HER2, and other genetic changes?
  • Would any of my results make me eligible for a targeted drug or a clinical trial?
  • Will I be offered chemotherapy after surgery?
  • Do I have liver disease that also needs treatment or monitoring?
  • How often will I have scans and blood tests after treatment?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?